Calpine (CPN) Reaches $13.25 After 3.00% Up Move; 3 Bullish Analysts Covering Myriad Genetics, Inc. (MYGN)

May 24, 2017 - By Kurt Siggers

Among 17 analysts covering Myriad Genetics (NASDAQ:MYGN), 3 have Buy rating, 4 Sell and 10 Hold. Therefore 18% are positive. Myriad Genetics had 32 analyst reports since July 21, 2015 according to SRatingsIntel. Morgan Stanley maintained Myriad Genetics, Inc. (NASDAQ:MYGN) rating on Wednesday, August 10. Morgan Stanley has “Underweight” rating and $21 target. The firm earned “Hold” rating on Thursday, August 11 by Jefferies. On Wednesday, August 10 the stock rating was maintained by UBS with “Sell”. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Underperform” rating by Bank of America on Friday, July 29. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Equal-Weight” rating given on Wednesday, November 2 by Stephens. The rating was upgraded by Ladenburg Thalmann on Wednesday, February 8 to “Neutral”. The company was downgraded on Wednesday, August 10 by Gabelli. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Buy” rating given on Tuesday, July 21 by Gabelli. Barclays Capital downgraded Myriad Genetics, Inc. (NASDAQ:MYGN) rating on Wednesday, August 10. Barclays Capital has “Equal-Weight” rating and $24 target. Avondale maintained the stock with “Market Outperform” rating in Wednesday, May 4 report. See Myriad Genetics, Inc. (NASDAQ:MYGN) latest ratings:

08/02/2017 Broker: Ladenburg Thalmann Old Rating: Sell New Rating: Neutral Upgrade
18/01/2017 Broker: Deutsche Bank Rating: Sell New Target: $15.00 Initiates Coverage On

The stock of Calpine Corporation (NYSE:CPN) is a huge mover today! About 608,387 shares traded. Calpine Corporation (NYSE:CPN) has declined 5.37% since May 24, 2016 and is downtrending. It has underperformed by 22.07% the S&P500.The move comes after 6 months positive chart setup for the $4.68 billion company. It was reported on May, 24 by Barchart.com. We have $13.65 PT which if reached, will make NYSE:CPN worth $140.40M more.

Among 14 analysts covering Calpine Corporation (NYSE:CPN), 8 have Buy rating, 0 Sell and 6 Hold. Therefore 57% are positive. Calpine Corporation had 29 analyst reports since July 31, 2015 according to SRatingsIntel. Deutsche Bank downgraded Calpine Corporation (NYSE:CPN) on Monday, November 2 to “Hold” rating. Citigroup maintained the stock with “Buy” rating in Tuesday, March 29 report. The rating was upgraded by Evercore to “Buy” on Friday, July 31. The firm has “Buy” rating given on Friday, July 31 by Deutsche Bank. SunTrust maintained the shares of CPN in report on Monday, March 7 with “Neutral” rating. The stock has “Buy” rating by BMO Capital Markets on Monday, May 1. The stock of Calpine Corporation (NYSE:CPN) has “Outperform” rating given on Tuesday, February 16 by RBC Capital Markets. Guggenheim initiated the stock with “Buy” rating in Friday, January 29 report. The stock of Calpine Corporation (NYSE:CPN) has “Neutral” rating given on Wednesday, August 24 by Suntrust Robinson. The stock of Calpine Corporation (NYSE:CPN) earned “Buy” rating by Citigroup on Friday, September 18.

Analysts await Calpine Corporation (NYSE:CPN) to report earnings on August, 4. They expect $0.01 earnings per share, down 83.33% or $0.05 from last year’s $0.06 per share. CPN’s profit will be $3.53 million for 331.25 P/E if the $0.01 EPS becomes a reality. After $-0.32 actual earnings per share reported by Calpine Corporation for the previous quarter, Wall Street now forecasts -103.13% EPS growth.

Calpine Corporation is a power generation company. The company has market cap of $4.68 billion. The Firm is engaged in the ownership and operation of primarily natural gas-fired and geothermal power plants in North America. It has a 20.2 P/E ratio. The Company’s divisions include West , Texas and East (including Canada).

Investors sentiment decreased to 0.93 in Q4 2016. Its down 0.31, from 1.24 in 2016Q3. It turned negative, as 53 investors sold Calpine Corporation shares while 94 reduced holdings. 42 funds opened positions while 95 raised stakes. 330.38 million shares or 1.86% less from 336.63 million shares in 2016Q3 were reported. Amp Capital Invsts Limited owns 93,677 shares. Northpointe Cap Ltd holds 0.05% or 40,034 shares. Clearbridge Limited Liability Corp holds 1.96% or 7.58M shares. Glenmede Tru Na has 0% invested in Calpine Corporation (NYSE:CPN) for 131 shares. Blackrock Japan Limited holds 462,049 shares. Shell Asset invested 0.01% in Calpine Corporation (NYSE:CPN). Round Table Services Llc accumulated 0.37% or 80,500 shares. Fuller & Thaler Asset Mngmt Inc has 0% invested in Calpine Corporation (NYSE:CPN). Regions Financial stated it has 0% of its portfolio in Calpine Corporation (NYSE:CPN). Point72 Asia (Hong Kong) Limited holds 0% or 95 shares. Moreover, Mufg Americas Hldgs has 0% invested in Calpine Corporation (NYSE:CPN). Moreover, Massachusetts Ma has 0.09% invested in Calpine Corporation (NYSE:CPN). 356,231 are owned by Caisse De Depot Et Placement Du Quebec. Barclays Public Ltd stated it has 0% in Calpine Corporation (NYSE:CPN). Brown Brothers Harriman & has invested 0% in Calpine Corporation (NYSE:CPN).

Myriad Genetics, Inc. is a molecular diagnostic company. The company has market cap of $1.36 billion. The Firm is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. It has a 33.48 P/E ratio. The Firm operates through two divisions: diagnostics and other.

Since February 22, 2017, it had 1 insider buy, and 0 insider sales for $111,930 activity. $111,930 worth of Myriad Genetics, Inc. (NASDAQ:MYGN) was bought by HENDERSON JOHN T on Wednesday, February 22.

About 38,076 shares traded. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 37.47% since May 24, 2016 and is downtrending. It has underperformed by 54.17% the S&P500.